Last $31.57 USD
Change Today +0.395 / 1.27%
Volume 96.3K
GHDX On Other Exchanges
Symbol
Exchange
GHDX is not on other exchanges.
As of 3:24 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

genomic health inc (GHDX) Snapshot

Open
$31.60
Previous Close
$31.17
Day High
$32.14
Day Low
$31.18
52 Week High
10/31/14 - $37.74
52 Week Low
05/7/14 - $23.90
Market Cap
1.0B
Average Volume 10 Days
155.5K
EPS TTM
$-0.88
Shares Outstanding
31.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENOMIC HEALTH INC (GHDX)

genomic health inc (GHDX) Related Businessweek News

View More BusinessWeek News

genomic health inc (GHDX) Details

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, facilitating physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as is used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.

684 Employees
Last Reported Date: 03/11/14
Founded in 2000

genomic health inc (GHDX) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $600.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $469.2K
Executive Vice President of Research & Develo...
Total Annual Compensation: $459.2K
Compensation as of Fiscal Year 2013.

genomic health inc (GHDX) Key Developments

Genomic Health, Inc. Announces Positive Results from the Second Large Clinical Validation Study of Oncotype DX in Patients with a Pre-Invasive Form of Breast Cancer

Genomic Health Inc. announced positive results from the second large clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group of Sunnybrook Health Sciences Centre in Canada, reconfirmed that the Oncotype DX DCIS Score is a strong predictor of local recurrence, which could be either invasive breast cancer or DCIS (p<0.001). This large genomic study in DCIS to date examined a broad, population-based cohort of more than 1,200 DCIS patient tumor samples collected from patients diagnosed with DCIS between 1994 and 2003 in Ontario, Canada. The primary analysis, presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), included 571 patients who were treated with breast-conserving surgery where the tumor was completely removed. The results, which are consistent with those of the original ECOG-ACRIN Cancer Research group clinical validation study, demonstrated that the DCIS Score quantified the 10 year risk of local recurrence beyond clinical factors such as tumor size and grade. This analysis clearly identified that the majority (62%) of studied DCIS patients were low risk based on the tumor biology revealed by the Oncotype DX test.

Genomic Health Announces Presentation of First Prospective Outcomes Study of Oncotype DX® Breast Cancer Test

Genomic Health Inc. announced early results from Europe's contemporary adjuvant breast cancer trial, which used the Oncotype DX® breast cancer test to identify higher-risk patients who would benefit from the treatment. The early results of the study, conducted by the Women's Healthcare Study Group (WSG), represent the first prospective outcomes data on prognosis supporting the use of Oncotype DX to guide whether to add chemotherapy to standard hormonal therapy in estrogen receptor positive breast cancer. The WSG trial was designed to evaluate the efficacy of an anthracyline-free adjuvant chemotherapy regimen and utilized the Oncotype DX breast cancer test to identify higher-risk patients who would be more likely to benefit from chemotherapy treatment. In the study of 3,198 patients, mostly qualified as candidates for chemotherapy by traditional parameters, patients with Recurrence Score® results of 12 or higher were randomized to one of two different chemotherapy regimens, and patients with Recurrence Score results of 11 or less were offered hormonal therapy alone. After nearly three years of follow-up, patients with Recurrence Score results of 11 or less had very high survival rates without evidence of recurrence (98.3%), despite having node-positive disease or high-risk node-negative disease by traditional parameters. Researchers will continue to follow patients and report results on drug treatment and longer-term outcomes.

Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests

Genomic Health Inc. announced positive results from its first two feasibility studies assessing multiple technologies, including next-generation sequencing, for their ability to detect and characterize the presence of bladder cancer DNA in urine and breast cancer DNA in blood. The presentations of these initial encouraging results at the 2014 San Antonio Breast Cancer Symposium (SABCS) and the 2014 Society of Urologic Oncology (SUO) Annual Meeting represent an important milestone as Genomic Health pursues the development of standardized non-invasive tests that can provide an ongoing evaluation of a patient's cancer to obtain quantitative real-time insights to inform treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. Solid tumors that originate in internal organs such as the breast or bladder often release DNA and tumor cells into the bloodstream or urine. When the presence of tumor-derived DNA in blood is high and persists or increases over time, the cancer is likely growing and a new course of treatment may be appropriate. In the two separate studies, Genomic Health researchers used the company's NGS- and PCR-based technologies and methods to detect tumor DNA and tumor DNA alterations in urine and blood. Three major alteration types were studied across various stages of breast and bladder cancers. Specifically, to identify the most accurate and efficient approach to detect cancer presence in a tumor sample, the company examined DNA copy number aberrations (CNAs), DNA methylation variations, and DNA single nucleotide variations (SNVs). Based on these promising results, Genomic Health is conducting larger-scale proof-of-concept studies investigating analytical methods that would enable accurate and scalable genomic analysis of liquid biopsies in breast and bladder cancer patients. The company plans to introduce its first liquid biopsy-based test in 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GHDX:US $31.57 USD +0.395

GHDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $22.46 USD +0.57
NanoString Technologies Inc $14.41 USD +0.07
NeoGenomics Inc $4.19 USD +0.08
Response Genetics Inc $0.43 USD +0.03
Veracyte Inc $7.78 USD +0.105
View Industry Companies
 

Industry Analysis

GHDX

Industry Average

Valuation GHDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.5x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOMIC HEALTH INC, please visit www.genomichealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.